Research Pipeline

Explore our portfolio of innovative therapies in various stages of development.

BG-2024-001Phase II

CRISPR-Cas9 Gene Editor for Sickle Cell Disease

Targeted gene correction therapy using proprietary delivery platform for durable cure.

Enrollment124/200
Sites28
StatusActive
BG-2024-002Phase I

CAR-T Cell Therapy for Pancreatic Cancer

Chimeric antigen receptor T-cell therapy targeting MUC16 expression in solid tumors.

Enrollment18/36
Sites12
StatusDosing
BG-2024-003Phase III

mRNA Vaccine for Influenza

Next-generation mRNA vaccine with universal coverage against all influenza strains.

Enrollment4,200/5000
Sites85
StatusActive
BG-2024-004Preclinical

Regenerative Heart Patch

Stem cell-derived cardiac tissue patch for post-MI regeneration and functional recovery.

StageIND-Enabling
Timeline2027
StatusTesting